PerspectivePharmacology

Leveraging unique structural characteristics of WNK kinases to achieve therapeutic inhibition

See allHide authors and affiliations

Science Signaling  18 Oct 2016:
Vol. 9, Issue 450, pp. pe3
DOI: 10.1126/scisignal.aaj2227

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

The with-no-lysine (K) WNK kinases are master regulators of the Na+-(K+)-Cl cotransporters, including the renal-specific NCC and NKCC2 cotransporters. The discovery of WNK463, an orally bioavailable pan-WNK kinase inhibitor that exploits unique structural properties of the WNK catalytic domain to achieve high affinity and kinase selectivity, illustrates a strategy of leveraging distinct kinase features to develop specific inhibitors and validates the genetic predictions of the in vivo pharmacology of WNK inhibition.

View Full Text

Stay Connected to Science Signaling